AP
Apogee Therapeutics, Inc.
APGE · NASDAQ
$135.07 +0.01% (+$0.01)
1M +0.21%
Market Cap $8.36B
P/E Ratio -
Div. Yield -
ROE 29.88%
Piotroski F-Score Weak
2/9Valuation
13 /100
Expensive P/B 7.00x
EV/FFO N/A
P/E N/A
Growth
100 /100
Growing Book val. growth 85.30%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor ROA 22.04%
ROIC 25.25%
Asset turnover 0.00x
Debt
69 /100
Low Int. coverage -185.14x
Debt/Equity 0.01x
Current ratio 26.44x
Stability
33 /100
Unstable Profitable years 0
Beta 0.34x
EPS volatility 44.58%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na APGE
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Thomas Henderson
Employees
261
Headquarters
Waltham
Nadcházející události
09 LIS
Earnings
Upcoming earnings report